V

Vtesse, Inc.

50 employees

Vtesse's lead compound, VTS-270, has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Type C (NPC)
Niemann-Pick Disease
Consumer Research
Drug Development
Rare Disease

Date founded

2014

Funding rounds raised

Total raised

$25M

from 4 investors over 4 rounds

V

Vtesse, Inc. raised $17M on July 25, 2016

Investors: Lundbeckfonden / Lundbeck Foundation and Bay City Capital

V

Vtesse, Inc. raised $25M on January 7, 2015

Investors: Lundbeckfonden / Lundbeck Foundation and Bay City Capital

FAQ